Quick Facts: Therapeutic Domains

• Acid-related conditions: Used for the management of heartburn, acid indigestion, and sour stomach.
• Reflux disease: Employed in the treatment of Gastroesophageal Reflux Disease (GERD).
• Ulcer management: Indicated for the management and healing support of both active gastric and duodenal ulcers.
• Hypersecretory conditions: Utilized for pathological conditions that involve excessive stomach acid production, such as Zollinger-Ellison syndrome.

---

Ацилок is a medication that assists in the management of conditions related to excessive stomach acid. Its primary use is to provide support in the short-term treatment of ulcers found in the stomach and small intestine, promoting a healing environment for the affected tissues. The compound may also be used for maintenance therapy to help sustain ulcer healing over a longer period.

The medication is frequently utilized to address the symptoms of Gastroesophageal Reflux Disease (GERD), a condition in which the backward flow of stomach acid can cause discomfort and irritation in the esophagus. The treatment aims to provide relief from associated symptoms, such as heartburn and acid reflux. Furthermore, this established agent is used in the management of specific hypersecretory conditions where the stomach produces unnaturally high levels of acid, which is vital for preventing related complications.

Regulatory References

1. NIH MedlinePlus guidance

Eligibility Map: Who can and cannot use Ацилок — Official Regulatory Information

The eligibility profile for using Ацилок (Ranitidine) is defined by official government regulatory documentation, which specifies both permitted populations and absolute contraindications.

Populations For Whom Use is Prohibited

Use of this medicine is formally contraindicated and strictly prohibited for two patient groups: individuals with a known history of hypersensitivity or allergic reaction to Ranitidine or any component of the formulation, and patients with a documented history of acute porphyria.

Age-Based Eligibility and Restrictions

Standard use is established for Adults and Adolescents (generally 12 years and older). Pediatric use is established for children down to approximately one month of age for specific indications, but use below this age is not routinely recommended. Use in Older Adults is generally permitted but often requires caution due to age-related decline in renal function.

Conditional Use and Restrictions

Use is restricted in patients with impaired renal function (kidney disease), who require a dosage adjustment as mandated by regulatory labeling due to reduced drug clearance. Use during pregnancy and lactation is generally not recommended or advised only if clearly needed, as the medicine is known to cross the placenta and is excreted into breast milk.

Interactions with other medicines and products

Official regulatory documentation describes that the interactions involving Ацилок (Ranitidine) are primarily pharmacokinetic, resulting in modifications to the plasma concentration of co-administered substances. No combinations are formally listed as contraindicated in major regulatory labels.

Documented Pharmacokinetic Interaction Patterns

Interaction Mechanism	Interacting Substances / Categories	Effect on Co-administered Drug
Gastric pH Elevation	Drugs requiring an acidic pH for absorption (e.g., Ketoconazole, Atazanavir)	Reduced absorption and decreased systemic exposure
Enzyme & Transporter Inhibition	Drugs cleared by hepatic mixed function oxidase systems (e.g., Triazolam) or renal tubular secretion (e.g., Procainamide)	Reduced clearance and increased plasma concentrations

Co-administration with high-potency antacids may require separation of doses, as simultaneous use can decrease the absorption of Ranitidine itself. Furthermore, official documentation notes that Ranitidine may be associated with an increase in the absorption of alcohol (ethanol). For patients with impaired renal function, Ranitidine plasma levels are increased, which may heighten interaction risks with other renally-cleared medicines.

H2 Receptor Antagonism and Secretory Pathway Modulation

Ацилок is primarily a competitive antagonist targeting the Histamine H2 receptors located on the gastric parietal cells. By binding to these receptors, the drug blocks histamine, a significant physiological stimulus for gastric acid secretion. This blockade interrupts the intracellular signaling cascade, preventing the rise of cyclic AMP (cAMP) and the subsequent activation and translocation of the H^+/ K^+-ATPase (the proton pump) to the cell membrane. The inhibition of the histamine-mediated pathway results in a reduction in gastric H^+ ion output and a consequent increase in the pH of the stomach contents. The increased pH subsequently causes the inactivation of the proteolytic enzyme pepsin. Separately, the drug exhibits a secondary systemic mechanism by acting as a reversible inhibitor of certain Cytochrome P450 (CYP) enzymes in the liver, which can alter the metabolic clearance rates of other compounds processed by the same pathways.

Official Administration Guidelines

Ацилок (Ranitidine) usage is structured by instructions defining the appropriate routes, standardized dosage patterns, and scheduling over time. The medicine is supplied for two principal routes: oral administration (utilizing tablets, syrup, or effervescent forms) for routine outpatient use, and parenteral administration (intramuscular or intravenous injection) for settings where oral intake is not feasible.

Dosing and Frequency

The schedule follows specific patterns. For active conditions such as ulcers, the standard adult oral dose is typically 150 mg twice daily or a single dose of 300 mg taken at bedtime. The duration of acute treatment is usually limited to four to eight weeks, followed by an optional long-term maintenance regimen of 150 mg once nightly, which may be sustained for up to one year. Oral tablets can be taken without regard to the timing of meals.

Preparation and Special Populations

Administration requires adherence to preparation rules: effervescent forms must be fully dissolved in water before consumption, and parenteral forms must be appropriately diluted before intravenous use. Guidelines indicate a dose reduction for patients with impaired renal function (creatinine clearance less than 50 mL/min), often reducing the dose frequency to once every 24 hours. Pediatric dosing is determined by the patient’s body weight (mg/kg). If a dose is missed, instructions advise taking it as soon as remembered; however, if it is near the time of the next dose, the missed dose should be skipped, and patients must not double the dose.

---

These parameters define a standardized, time-limited use protocol that strictly controls the route of delivery, the specific numerical dose, and the required preparation steps, ensuring consistent application according to guidelines.

Research evidence / Overview of Studies for Ацилок (Ranitidine)

The research foundation for ranitidine, the active compound in Ацилок, has been built over decades using various study types, primarily short-term and long-term randomized controlled trials (RCTs) and systematic reviews. The evidence has been evaluated in several conditions where gastric acid is a factor.

---

Research Evidence for Healing Ulcers in the Stomach and Small Intestine

Clinical research has explored the compound for use in conditions characterized by acute ulceration. Short-term, controlled trials were primarily used to investigate healing patterns in adults with endoscopically confirmed ulcers. Studies tracked patient-reported outcomes describing perceived discomfort, such as ulcer pain and the reporting of antacid consumption. Trials reported the measured rates of endoscopic healing observed over treatment periods generally lasting between four and eight weeks.

Data for certain groups remain insufficient when compared to the full range of modern treatments now available. Much of this core evidence was compiled before newer, more potent acid-suppressing compounds became widely used. Consequently, comparative evidence is lacking in large-scale studies that specifically place ranitidine against the current standard of care.

---

Evidence for Preventing Ulcer Recurrence (Maintenance Therapy)

To explore long-term stability, long-term RCTs were utilized in adults who had initial ulcer healing prior to study entry. These studies focused on preventing a future flare-up of the condition—known as recurrence. The primary outcome was the rate of ulcer recurrence confirmed by endoscopy, with follow-up durations extending for six months, one year, and sometimes longer.

---

Study Landscape for Acid Reflux Disease (GERD) and Esophagitis

Short-term controlled trials explored symptom patterns and measured changes in outcomes related to physical discomfort typically over two to twelve weeks. Research highlighted changes measured during the study period in terms of patient-reported outcomes, such as the frequency and severity of heartburn. Findings describe patterns observed in the studies related to the measured rates of endoscopic healing in mild to moderate esophagitis. The evidence regarding measured outcomes for severe forms of erosive esophagitis is less comprehensive than that for symptomatic relief.

---

Understanding the Long-Term Research and Evidence Gaps

While a significant volume of research exists for short-term use and maintenance, certainty remains low for long-term outcomes across all measured endpoints. Follow-up durations were limited in many studies of GERD and in the specific pediatric cohorts examined. Study results reflect the specific conditions under which they were conducted, and research does not determine whether an individual will respond similarly.

Key Studies & References

1. Ranitidine Oral: MedlinePlus Drug Information
2. Ranitidine for children: a double-blind, randomized, placebo-controlled trial in infants

Common questions about Ацилок (FAQ)

Q: What is the main reason doctors prescribe Ацилок?

A: Official labeling describes the medicine's use for conditions related to gastric acid. These indications include the short-term treatment of active duodenal ulcers and benign gastric ulcers. It is also used in the management of Gastroesophageal Reflux Disease (GERD) and for certain pathological hypersecretory conditions where excessive acid is produced.

Q: How quickly should someone expect Ацилок to start working?

A: The time until symptomatic relief is noted in official documentation. For conditions such as GERD and erosive esophagitis, symptomatic relief is described as commonly occurring within 24 hours after a person begins treatment.

Q: Does Ацилок cause long-term side effects?

A: When H₂-receptor antagonists like this medicine are used for long periods, regulatory documents have noted a potential concern regarding nutrient absorption. Specifically, long-term use may lead to reduced absorption of vitamin B12 from the diet.

Q: Do any common foods or drinks interfere with Ацилок?

A: Based on official documents, the effectiveness of the medicine is not significantly affected by food. The absorption of the active ingredient is described as not being substantially impaired by the administration of meals.

Q: Is there a generic version of Ацилок available?

A: Yes, the active ingredient is Ranitidine. Ranitidine is the official, non-branded (generic) compound name. This means that the medicine is available in generic forms recognized by official drug compendia.

Q: How long does the effect of one dose of Ацилок last?

A: Official clinical pharmacology data describes the duration of the medicine's effect. Following a standard dose, the concentration in the blood capable of significantly inhibiting gastric acid secretion is reported to remain in range for up to 12 hours.

Q: Can Ацилок affect the results of any medical tests?

A: Official product information describes potential changes that may appear in laboratory or blood test results. These changes can include shifts in liver function markers, low levels of certain blood components such as white blood cells or platelets, and an increase in blood creatinine.

Q: Does Ацилок have any restrictions related to driving or operating machinery?

A: The official documents include rare reports of effects on the nervous system, such as feeling dizzy or drowsy (somnolence). The official caution is that these effects may impair the ability to operate machinery or drive.

Q: Is it normal for me to still have some acid symptoms while taking Ацилок?

A: Regulatory guidance addresses situations where acid symptoms persist during treatment. Regulatory guidance notes that persistence of heartburn or acid symptoms for longer than two weeks, particularly in over-the-counter use, may indicate the need for further medical evaluation.

Q: Do you need a prescription to buy Ацилок?

A: Ranitidine, the active ingredient in the medicine, is supplied in both prescription and non-prescription (over-the-counter) formulations. The requirement for a prescription depends on the specific strength and dosage form being used.

Q: What is the difference between prescription-strength and over-the-counter Ацилок?

A: The key difference between the formulations relates to the specific concentrations and use protocols. Different strengths and treatment durations are regulated for either over-the-counter or prescription use.

Q: Is it true that taking Ацилок can affect B12 levels?

A: Regulatory documents have noted a potential connection between long-term use of H₂-receptor antagonists and B12 absorption. It is indicated that use over a prolonged period may prevent the normal absorption of vitamin B12 from the diet, potentially leading to a deficiency.

Q: Why is Ацилок sometimes compared to Ranitidine or Omeprazole by people online?

A: The compound in this medicine is Ranitidine, which is an H₂-receptor antagonist (an H₂-blocker). This mechanism functions differently than medicines known as Proton Pump Inhibitors (PPIs), such as Omeprazole, which block acid production at a different step.

Q: What are the symptoms of an allergic reaction to Ацилок?

A: Regulatory documents describe symptoms of a severe hypersensitivity (allergic) reaction. These reactions may include a raised, itchy rash (hives), swelling of the face or mouth (angioedema), chest pain, and difficulty breathing.

Q: Is Ацилок similar to Tagamet (Cimetidine)?

A: Official information describes this medicine as belonging to the Histamine H₂-receptor antagonist class. Other compounds, such as Cimetidine (historically branded as Tagamet) and Famotidine, also belong to this same pharmacological class.

Q: What are the main risks identified in large-scale studies of Ацилок?

A: Epidemiological studies have suggested an association between the use of H₂-receptor antagonists and a potential risk of developing pneumonia. Additionally, regulatory actions in some jurisdictions have been taken to address concerns regarding the presence of the impurity N-nitrosodimethylamine (NDMA).

Q: What are the most common reasons a doctor might tell a patient not to use Ацилок?

A: Use of this medicine is formally prohibited (contraindicated) for individuals with a history of allergic reaction to the compound or those diagnosed with acute porphyria. Regulatory agencies mandate that dose adjustments or special caution apply to patients who have impaired kidney (renal) or liver (hepatic) function.

Storage and Disposal Requirements for Aciloc (Ranitidine)

Storage and disposal of Aciloc (Ranitidine) must follow the conditions specified in official regulatory labeling to ensure product quality.

Storage Conditions

Aciloc must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). The product must be kept in its original container, tightly closed, and protected from moisture [NIH MedlinePlus]. A mandatory requirement is to store the medicine out of the reach and sight of children.

Disposal Instructions

Unused or expired Aciloc must be disposed of properly according to local regulations [FDA Labeling]. Regulatory guidance suggests utilizing local drug take-back programs or following the recommended household trash procedure for disposal.